The cardiovascular ailments are on the rise around the globe. Massive population comprising of young adults and senior citizens are becoming easy preys. The cardiovascular diseases are the prime cause of millions of premature deaths which occurs around the world. Every year almost 17 million people get killed by heart attacks or any other cardiovascular problem. The South-East Asian region of the world witnessed a steep rise in the cardiovascular deaths and the numbers are soaring with every passing day. Several healthcare elevations are made to wall the global growth of heart disease.
According to a report published by Future Market Insights (Future Market Insights), global balloon catheter market is projected to expand at a CAGR of 3.8% during the forecast period and is expected to be valued at US$ 4,191.7 million by the end of 2026. The global balloon catheter market is expected to represent US$ 1,304.3 Mn in terms of incremental opportunity between 2016 and 2026. The balloon catheter market is further segmented into several categories. Amongst them, the drug eluting balloon catheter segment is expected to expand at a significant CAGR of 20.0% over the forecast period owing to the unique benefits offered by these balloon catheters in the treatment of Coronary Artery Disease (CAD). The drug-eluting balloon catheters are mostly preferred by medical practitioners for several benefits that it offers. It completely shuns an inflammatory reaction and minimises chances of infection. They are dominating the present balloon catheter market. They are widely used to prevent restenosis. The DEB technology has revolutionised the entire cardiovascular treatment process.
The drug eluting balloon catheter has a wider and accurate impact on the patient. The tool possesses a better capability of releasing proper dosage of the drug and reduces the time of healing. It has adapted to the market needs and evolved its technology to meet the patient’s requirements. They have the capability to affect the entire vessel wall which further brings down the agony of the patient. The device is tailor made to reduce any sort of thrombosis. In this process, no stent is used which helps in keeping the structure of the artery intact. Through this, a unique drug delivery channel can be crated which can curtail down the chances of antiplatelet therapy. This new tool is cost effective and escalates the convenience level of the patient in a long process of treatment. To know more ask for a free sample https://www.futuremarketinsights.com/reports/sample/rep-gb-1916